Jane Sui (@janesysui) 's Twitter Profile
Jane Sui

@janesysui

Advanced Medical Oncology Fellow at Memorial Sloan Kettering Cancer Center. Interested in thoracic oncology. From Malaysia to Ireland and now in New York

ID: 1552873993316827137

calendar_today29-07-2022 04:30:02

4 Tweet

73 Followers

71 Following

Eric K. Singhi, MD (@lungoncdoc) 's Twitter Profile Photo

🚨You’re going to want to BOOKMARK this one #OncTwitter #LCSM OncoAlert 👇🏽 Depicts why: 1️⃣ NGS in early-stage dz is becoming more relevant 2️⃣ Shared decision-making matters 3️⃣ Personalized medicine is important #ASCO23 Julia Rotow MD Jill Feldman Deepa Rangachari, MD, FASCO Delvys Rodriguez Abreu

🚨You’re going to want to BOOKMARK this one #OncTwitter #LCSM <a href="/OncoAlert/">OncoAlert</a> 

👇🏽 Depicts why: 
1️⃣ NGS in early-stage dz is becoming more relevant 
2️⃣ Shared decision-making matters
3️⃣ Personalized medicine is important

#ASCO23 <a href="/JuliaRotow/">Julia Rotow MD</a> <a href="/jillfeldman4/">Jill Feldman</a> <a href="/DeepaRangachari/">Deepa Rangachari, MD, FASCO</a> <a href="/delvysra/">Delvys Rodriguez Abreu</a>
Journal of Clinical Oncology (@jco_asco) 's Twitter Profile Photo

Lead author Gʀᴇɢᴏʀʏ Rɪᴇʟʏ of Memorial Sloan Kettering Cancer Center: "Overall, this shows efficacy for both first-line and second-line use of encorafenib and binimetinib for patients with BRAFV600E-mutant metastatic NSCLC." Read the paper: fal.cn/3yNV0 #ASCO23 #lcsm